221 related articles for article (PubMed ID: 27876874)
1. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling.
Roberts CM; Tran MA; Pitruzzello MC; Wen W; Loeza J; Dellinger TH; Mor G; Glackin CA
Sci Rep; 2016 Nov; 6():37652. PubMed ID: 27876874
[TBL] [Abstract][Full Text] [Related]
2. Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-κB-mediated IKKβ expression.
Wu YH; Huang YF; Chang TH; Chou CY
Int J Cancer; 2017 Dec; 141(11):2305-2317. PubMed ID: 28815582
[TBL] [Abstract][Full Text] [Related]
3. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
4. miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.
Zhu X; Shen H; Yin X; Long L; Xie C; Liu Y; Hui L; Lin X; Fang Y; Cao Y; Xu Y; Li M; Xu W; Li Y
Oncogene; 2016 Jan; 35(3):323-32. PubMed ID: 25867064
[TBL] [Abstract][Full Text] [Related]
5. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells.
Li QQ; Xu JD; Wang WJ; Cao XX; Chen Q; Tang F; Chen ZQ; Liu XP; Xu ZD
Clin Cancer Res; 2009 Apr; 15(8):2657-65. PubMed ID: 19336515
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Nicotra MR; Lucidi A; Ferrandina G; Natali PG; Bagnato A
Clin Cancer Res; 2011 Apr; 17(8):2350-60. PubMed ID: 21220476
[TBL] [Abstract][Full Text] [Related]
7. Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the β-catenin and Akt pathways.
Way TD; Huang JT; Chou CH; Huang CH; Yang MH; Ho CT
Eur J Cancer; 2014 Jan; 50(2):366-78. PubMed ID: 24157255
[TBL] [Abstract][Full Text] [Related]
8. Akt inhibitor SC66 promotes cell sensitivity to cisplatin in chemoresistant ovarian cancer cells through inhibition of COL11A1 expression.
Wu YH; Huang YF; Chen CC; Chou CY
Cell Death Dis; 2019 Apr; 10(4):322. PubMed ID: 30975980
[TBL] [Abstract][Full Text] [Related]
9. Akt/PKB-mediated phosphorylation of Twist1 promotes tumor metastasis via mediating cross-talk between PI3K/Akt and TGF-β signaling axes.
Xue G; Restuccia DF; Lan Q; Hynx D; Dirnhofer S; Hess D; Rüegg C; Hemmings BA
Cancer Discov; 2012 Mar; 2(3):248-59. PubMed ID: 22585995
[TBL] [Abstract][Full Text] [Related]
10. miR-181a-Twist1 pathway in the chemoresistance of tongue squamous cell carcinoma.
Liu M; Wang J; Huang H; Hou J; Zhang B; Wang A
Biochem Biophys Res Commun; 2013 Nov; 441(2):364-70. PubMed ID: 24148247
[TBL] [Abstract][Full Text] [Related]
11. Twist1-induced epithelial-mesenchymal transition according to microsatellite instability status in colon cancer cells.
Oh BY; Kim SY; Lee YS; Hong HK; Kim TW; Kim SH; Lee WY; Cho YB
Oncotarget; 2016 Aug; 7(35):57066-57076. PubMed ID: 27494849
[TBL] [Abstract][Full Text] [Related]
12. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells.
Yoon H; Min JK; Lee DG; Kim DG; Koh SS; Hong HJ
Cancer Lett; 2012 Mar; 316(1):70-6. PubMed ID: 22088438
[TBL] [Abstract][Full Text] [Related]
13. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
Chong KY; Kang M; Garofalo F; Ueno D; Liang H; Cady S; Madarikan O; Pitruzzello N; Tsai CH; Hartwich TMP; Shuch BM; Yang-Hartwich Y
Mol Pharmacol; 2019 Aug; 96(2):168-179. PubMed ID: 31175180
[TBL] [Abstract][Full Text] [Related]
15. The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.
Tan M; Asad M; Heong V; Wong MK; Tan TZ; Ye J; Kuay KT; Thiery JP; Scott C; Huang RY
Mol Oncol; 2019 Apr; 13(4):757-780. PubMed ID: 30548372
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway.
Zhang LY; Shen ZX; Guo L
Cancer Invest; 2022 Apr; 40(4):313-324. PubMed ID: 35040385
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of PLOD3 suppresses the malignant progression of renal cell carcinoma via reducing TWIST1 expression.
Xie D; Li J; Wei S; Qi P; Ji H; Su J; Du N; Zhang X
Mol Cell Probes; 2020 Oct; 53():101608. PubMed ID: 32585183
[TBL] [Abstract][Full Text] [Related]
18. Involvement of microRNA-93, a new regulator of PTEN/Akt signaling pathway, in regulation of chemotherapeutic drug cisplatin chemosensitivity in ovarian cancer cells.
Fu X; Tian J; Zhang L; Chen Y; Hao Q
FEBS Lett; 2012 May; 586(9):1279-86. PubMed ID: 22465665
[TBL] [Abstract][Full Text] [Related]
19. Twist1 regulates the epithelial-mesenchymal transition via the NF-κB pathway in papillary thyroid carcinoma.
Lv N; Shan Z; Gao Y; Guan H; Fan C; Wang H; Teng W
Endocrine; 2016 Mar; 51(3):469-77. PubMed ID: 26289126
[TBL] [Abstract][Full Text] [Related]
20. ARTEMIN synergizes with TWIST1 to promote metastasis and poor survival outcome in patients with ER negative mammary carcinoma.
Banerjee A; Wu ZS; Qian P; Kang J; Pandey V; Liu DX; Zhu T; Lobie PE
Breast Cancer Res; 2011; 13(6):R112. PubMed ID: 22060274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
